







an Open Access Journal by MDPI

### **Blood Stem Cells in Pre-leukaemia**

Guest Editor:

**Dr. Christopher I. Slape** The University of Queensland

Deadline for manuscript submissions:

closed (1 June 2021)

Diamantina Institute

## Message from the Guest Editor

While all cancers pass through an intermediate premalignancy phase before reaching the threshold of malignancy, we have more knowledge of this phase in the haematopoietic system than in most other tissues. Premalignant conditions in the haematopoietic system include the clinically presenting myelodysplastic syndrome and myeloproliferative neoplasms, the recently identified clonal haematopoiesis of indeterminate potential, the modelled pre-leukemic thymocytes that precede T-cell acute lymphoblastic leukaemia (T-ALL), aplastic anaemia, bone marrow failure conditions and others. This Special Issue of *Cancers* will include reviews and primary research articles on the abnormal properties of stem and progenitor cells in these different diseases, the mechanisms that can drive the transformation to overt leukaemia and how these may be targeted or adapted therapeutically.













an Open Access Journal by MDPI

## **Editor-in-Chief**

#### Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

# **Message from the Editor-in-Chief**

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

### **Author Benefits**

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

#### **Contact Us**